On April 17, 2023 Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN), a clinical-stage company developing targeted immunotherapeutic drugs, reported that the company will host a webcast to share data from its SB101 clinical study with SON-1010 in oncology patients (NCT05352750) on Tuesday, April 18, 2023 at 5:00 pm ET (Press release, Sonnet BioTherapeutics, APR 17, 2023, View Source [SID1234630173]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Webcast presenters will include:
Richard Kenney, M.D., Chief Medical Officer
Pankaj Mohan, Ph.D., Sonnet Founder and Chief Executive Office
The webcast at 5:00 pm ET, with an accompanying presentation, will be accessible under News & Events, IR Calendar in the Investors section of the company’s website. The archived audio webcast will be available on Sonnet’s website following the call.
To participate in the webcast, please see the following details:
Webcast Link: View Source;tp_key=f6d5c78778
Toll Free: 1-877-869-3847
International: 201-689-8261
Conference ID: 13737737
AACR Poster Presentation Details:
Title: Clinical development of a novel form of interleukin-12 with extended pharmacokinetics
Session Title: Phase I and First-in-Human Clinical Trials in Progress
Presentation Type: Poster
Session Date and Time: Tuesday April 18, 2023, 1:30 pm – 5:00 pm ET
Abstract Number: CT245
Location: Poster Section 46